Jason Kjono
Physician Assistant · Great Falls, MTNPI 1427199009
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by AstraZeneca at 56.8% of the total. Reporting peaked in 2022 at $12,825 and has fallen 86.8% since, to $1,693 in 2025. Among physician assistant clinicians in MT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 290 payments — averaging $109.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$18K
- GSK$5K
- Regeneron Healthcare Solutions, Inc.$5K
- Actelion Pharmaceuticals US, Inc.$559
- Boehringer Ingelheim$423
- Sanofi$375
- plus $2K from 14 others
What the payments were for
- Consulting fees$2,0707%
- Speaking & faculty fees$18,95060%
- Travel & lodging$4,97116%
- Food & beverage$5,19916%
- Education$5722%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 78 | $18,053 |
| GSK | 59 | $5,485 |
| Regeneron Healthcare Solutions, Inc. | 30 | $5,323 |
| Actelion Pharmaceuticals US, Inc. | 24 | $559 |
| Boehringer Ingelheim | 23 | $423 |
| Sanofi | 20 | $375 |
| Sanofi-aventis U.S. LLC | 4 | $349 |
| Insmed, Inc. | 7 | $241 |
| Mylan Specialty L.p. | 10 | $193 |
| Genentech USA, Inc. | 7 | $142 |
| Merck | 7 | $139 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $125 |
| Viatris Specialty LLC | 4 | $99 |
| Grifols USA, LLC | 4 | $81 |
| Amgen | 2 | $47 |
| Baxter Healthcare | 1 | $31 |
| Novartis | 1 | $29 |
| Advanced Respiratory, Inc | 1 | $25 |
| Verona Pharma, Inc. | 1 | $25 |
| United Therapeutics Corporation | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$31,763 in reported general payments places this provider in the 95th percentile of 626 physician assistant providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 806 | $701,686 |
| Dupixent PenDupilumab | 140 | $502,363 |
| TezspireTezepelumab-Ekko | 48 | $193,264 |
| Breo ElliptaFluticasone/Vilanterol | 212 | $112,010 |
| Spiriva RespimatTiotropium Bromide | 181 | $111,891 |
| EsbrietPirfenidone | 11 | $107,324 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 125 | $89,456 |
| XolairOmalizumab | 14 | $52,227 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 71 | $46,137 |
| NucalaMepolizumab | 11 | $40,457 |
| Advair HfaFluticasone Propion/Salmeterol | 101 | $35,737 |
| SymbicortBudesonide/Formoterol Fumarate | 103 | $31,410 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 192 | $30,646 |
| Spiriva HandihalerTiotropium Bromide | 41 | $29,321 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 611 | $27,316 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Incruse Ellipta, Anoro Ellipta | $5,485 | $922,2881,187 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort, Pulmicort Flexhaler | $18,053 | $317,826295 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $423 | $158,028252 claims |
| Genentech USA, Inc.Esbriet | $142 | $107,32411 claims |
| MerckDulera | $139 | $7,99619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 626 physician assistant providers in Montana.
Other physician assistant in Great Falls
- Morgan UmphresGreat Falls$3K
- Katie BrownGreat Falls$2K
- Katrina PaulsonGreat Falls$2K
- Jason EnewoldGreat Falls$2K
- Christopher MerchantGreat Falls$2K
- Trenay HartBillings$57K
- Maura KingKalispell$9K
- Joan Bond-DeschampsMissoula$9K
- Kasie CooperHelena$9K
- Janel Allison-ShamblinBozeman$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.